Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barbara Mora

Showing results (51-60 of 63) with videos related to

Pageof 7
Sort By:
Ejhaem|August 21, 2023
Incidence of blast phase in myelofibrosis according to anemia severityBarbara Mora, Margherita Maffioli, Elisa Rumi, et al.
Blood Advances|March 5, 2021
Gene expression profile correlates with molecular and clinical features in patients with myelofibrosisSebastiano Rontauroli, Sara Castellano, Paola Guglielmelli, et al.
Cancers|October 13, 2021
Increased Plasma Levels of lncRNAs <i>LINC01268</i>, <i>GAS5</i> and <i>MALAT1</i> Correlate with Negative Prognostic Factors in MyelofibrosisSebastian Fantini, Sebastiano Rontauroli, Stefano Sartini, et al.
Antioxidants (Basel, Switzerland)|January 21, 2022
The Response to Oxidative Damage Correlates with Driver Mutations and Clinical Outcome in Patients with MyelofibrosisElena Genovese, Margherita Mirabile, Sebastiano Rontauroli, et al.
Leukemia|August 23, 2024
Chromosome 9p trisomy increases stem cells clonogenic potential and fosters T-cell exhaustion in JAK2-mutant myeloproliferative neoplasmsChiara Carretta, Sandra Parenti, Matteo Bertesi, et al.
Leukemia|August 30, 2022
Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patientsBarbara Mora, Paola Guglielmelli, Andrew Kuykendall, et al.
The Lancet. Haematology|January 21, 2021
Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trialTiziano Barbui, Alessandro Maria Vannucchi, Valerio De Stefano, et al.
NEJM Evidence|February 6, 2024
Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia VeraTiziano Barbui, Alessandro Maria Vannucchi, Valerio De Stefano, et al.
Blood|March 5, 2026
Genomic profiling for decision-making in post-polycythemia vera and post-essential thrombocythemia myelofibrosisBarbara Mora, Francesca Palandri, Paola Guglielmelli, et al.
Blood|August 8, 2024
Proposals for revised International Working Group-European LeukemiaNet criteria for anemia response in myelofibrosisAyalew Tefferi, Giovanni Barosi, Francesco Passamonti, et al.
Pageof 7

Showing results (51-60 of 63) with videos related to

Sort By:
Pageof 7
Ejhaem|August 21, 2023
Incidence of blast phase in myelofibrosis according to anemia severityBarbara Mora, Margherita Maffioli, Elisa Rumi, et al.
Blood Advances|March 5, 2021
Gene expression profile correlates with molecular and clinical features in patients with myelofibrosisSebastiano Rontauroli, Sara Castellano, Paola Guglielmelli, et al.
Cancers|October 13, 2021
Increased Plasma Levels of lncRNAs <i>LINC01268</i>, <i>GAS5</i> and <i>MALAT1</i> Correlate with Negative Prognostic Factors in MyelofibrosisSebastian Fantini, Sebastiano Rontauroli, Stefano Sartini, et al.
Antioxidants (Basel, Switzerland)|January 21, 2022
The Response to Oxidative Damage Correlates with Driver Mutations and Clinical Outcome in Patients with MyelofibrosisElena Genovese, Margherita Mirabile, Sebastiano Rontauroli, et al.
Leukemia|August 23, 2024
Chromosome 9p trisomy increases stem cells clonogenic potential and fosters T-cell exhaustion in JAK2-mutant myeloproliferative neoplasmsChiara Carretta, Sandra Parenti, Matteo Bertesi, et al.
Leukemia|August 30, 2022
Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patientsBarbara Mora, Paola Guglielmelli, Andrew Kuykendall, et al.
The Lancet. Haematology|January 21, 2021
Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trialTiziano Barbui, Alessandro Maria Vannucchi, Valerio De Stefano, et al.
NEJM Evidence|February 6, 2024
Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia VeraTiziano Barbui, Alessandro Maria Vannucchi, Valerio De Stefano, et al.
Blood|March 5, 2026
Genomic profiling for decision-making in post-polycythemia vera and post-essential thrombocythemia myelofibrosisBarbara Mora, Francesca Palandri, Paola Guglielmelli, et al.
Blood|August 8, 2024
Proposals for revised International Working Group-European LeukemiaNet criteria for anemia response in myelofibrosisAyalew Tefferi, Giovanni Barosi, Francesco Passamonti, et al.
Pageof 7